...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.
【24h】

Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.

机译：接受氯氮平的门诊患者中的糖尿病：患病率与临床人口统计学相关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Treatment with antipsychotic drugs has been associated with increased risk for developing diabetes mellitus. Recent consensus statements suggest that clozapine may pose an especially high risk. The purpose of this study is to examine the prevalence and clinical-demographic correlates of diabetes among outpatients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder receiving clozapine. METHOD: One hundred one outpatients receiving clozapine at the University of Rochester Department of Psychiatry, Rochester, N.Y., were evaluated between September 2002 and September 2003. Demographic data were collected from medical records, and body mass index (BMI) and body fat measurements were conducted. Diagnosis of diabetes was established through review of medical records and fasting blood glucose testing. Associations between clinical and demographic variables and diabetes were examined using t tests, Fisher exact tests, and logistic regression. RESULTS: Mean (SD) age of patients was 40.4 (9.5) years, and 79% were white. Mean (SD) dose and duration of clozapine treatment were 426 (164) mg/day and 5.7 (3.6) years, respectively. Point prevalence of diabetes was 25.7%. Mean (SD) BMI was 32.6 (8.0) kg/m(2), and mean (SD) body fat was 34.0% (11.0%). Logistic regression revealed significant associations between diabetes and nonwhite race/ethnicity and family history of diabetes (p = .02 and .002, respectively). No significant associations were found between diabetes prevalence and BMI or body fat. CONCLUSION: Patients receiving clozapine are at substantial risk for developing diabetes, although the level of risk relative to other antipsychotic medications has not been fully determined. Clinicians should monitor all severely mentally ill patients receiving antipsychotic drugs for diabetes, with closer monitoring of patients with established demographic risk factors.
机译：背景：使用抗精神病药治疗与罹患糖尿病的风险增加有关。最近的共识声明表明，氯氮平可能构成特别高的风险。这项研究的目的是检查患有氯氮平的DSM-IV诊断为精神分裂症或精神分裂症的门诊患者中糖尿病的患病率和临床人口统计学相关性。方法：在2002年9月至2003年9月之间，对纽约州罗彻斯特市罗切斯特大学精神病学系的110名接受氯氮平的门诊患者进行了评估。从医疗记录中收集人口统计学数据，并进行体重指数（BMI）和体脂测量进行。糖尿病的诊断是通过查阅病历和空腹血糖测试来确定的。使用t检验，Fisher精确检验和logistic回归检查了临床和人口统计学变量与糖尿病之间的关联。结果：患者的平均（SD）年龄为40.4（9.5）岁，其中79％为白人。氯氮平治疗的平均（SD）剂量和持续时间分别为426（164）mg /天和5.7（3.6）年。糖尿病的点流行率为25.7％。平均（SD）体重指数为32.6（8.0）kg / m（2），平均（SD）体脂为34.0％（11.0％）。 Logistic回归显示糖尿病与非白人种族/族裔和糖尿病家族史之间存在显着关联（分别为p = .02和.002）。糖尿病患病率与BMI或体脂之间无显着关联。结论：尽管尚未完全确定相对于其他抗精神病药物的风险水平，但接受氯氮平的患者罹患糖尿病的风险很高。临床医生应监视所有接受抗精神病药物治疗的严重精神疾病患者的糖尿病，并密切监视具有确定的人口统计学危险因素的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号